| Revenue growth | Standalone up 14% YoY; Consolidated down 8% YoY. |
|---|---|
| Margins | Standalone Gross Margins improved to 78% from 69%. |
| Demand visibility | Strong poultry demand; Animal health impacted by tender timing. |
| Management confidence | Confident in long-term growth despite short-term tender delays. |
Growth
Standalone revenue grew 14% YoY; Poultry Healthcare rose 48% due to higher institutional sales. Consolidated revenue fell 8% on Africa/Nepal weakness.
Outlook
Management focuses on expanding market penetration and strengthening biologicals portfolio across Poultry and Animal Healthcare divisions.
Risks
Animal Healthcare segment down 50% due to government tender delays. Profitability heavily dependent on one-time accounting gains.
Last quarter's promises, checked
Delivered
- Guided focus on bottom line → delivered Standalone PAT up 174% (= BEAT)
- Guided stronger execution in Poultry → delivered 41% Q4 segment growth (= BEAT)
- Targeted debt reduction → delivered debt reduced from INR 102cr to INR 70cr (= BEAT)
Partly delivered
- Targeted BSL-3 facility ramp-up → delivered ongoing optimization initiatives (= PARTIAL)
Missed
- Guided Animal Health recovery → delivered segment revenue down 50% (= MISS)
Earnings Call Transcript filed with NSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,165.30
- Market cap
- ₹1,842 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.5×Sector 47.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences Annual General Meeting
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Other Announcement
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences Results Update
Hester Biosciences reported Q1 FY27 results, with standalone revenue up 14% to ₹72.60 Crore and profit growing 88% to ₹14.71 Crore.
- Value
- ₹72.66 Cr